Caladrius Biosciences Inc
LSE:0HS8
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C
|
Caladrius Biosciences Inc
LSE:0HS8
|
US |
|
Yatas Yatak ve Yorgan Sanayi Ticaret AS
IST:YATAS.E
|
TR |
|
Bigbloc Construction Ltd
NSE:BIGBLOC
|
IN |
Multiples-Based Value
The Multiples-Based Value of one 0HS8 stock under the Base Case scenario is 0.71 USD. Compared to the current market price of 4.73 USD, Caladrius Biosciences Inc is Overvalued by 85%.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Multiples Across Competitors
0HS8 Competitors Multiples
Caladrius Biosciences Inc Competitors
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
C
|
Caladrius Biosciences Inc
LSE:0HS8
|
91.7m USD | 539.2 | -5.5 | -4.2 | -4.2 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
368.7B USD | 5.9 | 86.9 | 14.4 | 20.1 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
189.2B USD | 5.1 | 24.1 | 14 | 14 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
174.3B USD | 5.9 | 20.2 | 12.6 | 15.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
112.8B USD | 9.3 | 28.2 | 21.2 | 22.1 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.9B USD | 5.4 | 17.3 | 12.8 | 14.6 | |
| NL |
|
argenx SE
XBRU:ARGX
|
43.6B EUR | 12.4 | 39.7 | 43.1 | 44 | |
| AU |
|
CSL Ltd
ASX:CSL
|
66.6B AUD | 3 | 33 | 11.1 | 13.9 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 |